Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Conditions
Interventions
AXS-05
Bupropion
+1 more
Locations
78
United States
Axsome Study Site
Gilbert, Arizona, United States
Axsome Study Site
Phoenix, Arizona, United States
Axsome study site
Scottsdale, Arizona, United States
Axsome study site
Scottsdale, Arizona, United States
Axsome Study Site
Tucson, Arizona, United States
Axsome Study Site
Little Rock, Arkansas, United States
Start Date
July 13, 2017
Primary Completion Date
April 17, 2020
Completion Date
April 17, 2020
Last Updated
September 13, 2023
NCT07545473
NCT04570085
NCT07531732
NCT06501495
NCT07290387
NCT06121544
Lead Sponsor
Axsome Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions